Clinical data
Trade namesLuvatren (discontinued)
ATC code
Legal status
Legal status
  • 1-(4-fluorophenyl)-4-[4-hydroxy-4-(4-methylphenyl)piperidin-1-yl]butan-1-one
CAS Number
PubChem CID
CompTox Dashboard (EPA)
ECHA InfoCard100.012.625 Edit this at Wikidata
Chemical and physical data
Molar mass355.453 g·mol−1
3D model (JSmol)
  • CC1=CC=C(C=C1)C1(O)CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1
  • InChI=1S/C22H26FNO2/c1-17-4-8-19(9-5-17)22(26)12-15-24(16-13-22)14-2-3-21(25)18-6-10-20(23)11-7-18/h4-11,26H,2-3,12-16H2,1H3

Moperone (Luvatren, since discontinued) is a typical antipsychotic of the butyrophenone class[2] which is marketed in Japan for the treatment of schizophrenia. It is an antagonist for the D2 (Ki 0.7–1.9 nM), D3 (Ki 0.1–1 nM), and 5-HT2A (Ki 52 nM) receptors. It also has a high binding affinity for the sigma receptors.[3][4]


  1. ^ Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-16.
  2. ^ Gross H, Kaltenbäck E (1969). "The clinical position of moperone among the butyrophenones". Nordisk Psykiatrisk Tidsskrift. Nordic Journal of Psychiatry. 23 (1): 4–9. doi:10.3109/08039486909132154. PMID 5354545.
  3. ^ Miyamoto S (2010). "Moperone". In Stolerman IP (ed.). Encyclopedia of Psychopharmacology. Berlin, Heidelberg: Springer. p. 798. doi:10.1007/978-3-540-68706-1_1838. ISBN 978-3-540-68706-1. Retrieved 21 March 2022.
  4. ^ Roth BL, Driscol J. "PDSP Ki Database". Psychoactive Drug Screening Program (PDSP). University of North Carolina at Chapel Hill and the United States National Institute of Mental Health. Retrieved 21 March 2022.